Betta Pharma Licenses Inventisbio's D-0316 to Treat Non-Small Cell Lung Cancer (NSCLC)
Shots:
- InventisBio to receive 36.4M including upfront- sales and R&D milestone and royalties on sales and will co-develop D-0316 in China with Betta Pharma. Betta Pharma to get exclusive commercialization rights of D-0316 in China- Hong Kong and Taiwan
- The focus of the agreement is to expand and strengthen Betta Pharma’s portfolio in lung cancer treatment
- InventisBio’s D-0316 is a third-generation EGFR-T790M tyrosine kinase inhibitor- evaluated in P-I for the treatment of EGFR-mutant NSCLC in China
Ref: Prnewswire | Image: Twitter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
